Table 1:

Demographics and clinical characteristics of both groups

Characteristic	AIFR Group	Control Group	P Value
Age (yr)^{^a}	49.5 ± 21.2 (2–85)	46.7 ± 21.2 (2–75)	.54
Male	20	25
Female	22	17
White blood cell count (× 1000/mm³)^{^a,^b}	0.9 ± 1.5 (0–6)	4.5 ± 12.4 (0.1–65.6)	.3
Absolute neutrophil count (× 1000/mm³)^{^a,^b}	0.51 ± 1.2 (0–4.9)	1.8 ± 4.0 (0–20.3)	.66
No. of patients <500/mm^{3^b}	60% (18/30)	57.1% (20/35)
No. of patients <1000 mm^{3^b}	83.3% (25/30)	68.6% (24/35)
Time from CT to treatment (days)	0.95 ± 1.1	0.83 ± 0.82	.57
Follow-up time (days)^{^a}	412.9 ± 587.5 (2–2836)	346.7 ± 402.4 (18–2174)	.56
Deceased from AIFR	7^{^c}	0
Deceased not from AIFR	14	9
Not deceased	20	33
Overall mortality	52% (22/42)	21% (9/42)	.003
AIFR-related mortality	17% (7/41)^{^a}	0% (0/42)
Non-AIFR related mortality	34% (14/41)^{^a}	21% (9/42)

↵a Data are reported as mean, with range in parentheses.
↵b Calculated only in patients with hematologic malignancy (including multiple myeloma) or bone marrow transplant.
↵c One patient was excluded because the cause of death was uncertain, reported as died with concomitant fulminant liver failure and AIFR.